Teva and Sanofi's Duvakitug Shows Promise in Phase 2b Trial for IBD, Shares Surge

Dec 17, 2024, 03:45 PM

Teva Pharmaceutical Industries and Sanofi have announced positive results from a Phase 2b clinical trial named RELIEVE UCCD for their drug, Duvakitug, which targets ulcerative colitis and Crohn's disease. The trial showed that Duvakitug met its primary endpoints, with 36.2% of ulcerative colitis patients on a low dose and 47.8% on a high dose achieving clinical remission, compared to 20.45% on placebo. For Crohn's disease, 26.1% of patients on a low dose and 47.8% on a high dose achieved an endoscopic response, compared to 13% on placebo. The drug was well tolerated with no safety signals identified. Following these results, Teva's shares surged by nearly 20%, while Sanofi's shares climbed by almost 5%. The companies plan to initiate Phase 3 development pending regulatory discussions.